NCT03932903 Mobile Health Intervention to Support Oral Chemotherapy Adherence in Adolescents and Young Adults With Leukemia
| NCT ID | NCT03932903 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Northwestern University |
| Condition | Acute Lymphoblastic Leukemia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-07-31 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-07-31 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a small-scale micro-randomized clinical trial of a new mobile just-in-time adaptive intervention (JITAI) designed to promote oral chemotherapy adherence in adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL). The goals of this study are to determine intervention feasibility and acceptability.
Eligibility Criteria
AYA Inclusion Criteria: * Ages 14-29 * Diagnosed with acute lymphoblastic leukemia (ALL) or lymphoma * In the maintenance phase, completed at least one cycle and has at least one month of maintenance therapy remaining. * Prescribed 6-mercaptopurine (6MP) * English language proficiency * For AYA \<18, must have informed consent from their caregiver. AYA Exclusion Criteria: * Cognitive impairments that would limit ability to complete measures, determined by the medical team * Absence of inclusion criteria above. Caregiver Inclusion Criteria: * Nominated by the AYA as a primary caregiver involved in cancer care (can be a parent, relative, partner, friend) * English language proficiency Caregiver Exclusion Criteria: \- Absence of inclusion criteria above.
Contact & Investigator
Alexandra M Psihogios, Ph.D.
PRINCIPAL INVESTIGATOR
Northwestern University
Frequently Asked Questions
Who can join the NCT03932903 clinical trial?
This trial is open to participants of all sexes, aged 14 Years or older, studying Acute Lymphoblastic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03932903 currently recruiting?
Yes, NCT03932903 is actively recruiting participants. Contact the research team at alex.psihogios@northwestern.edu for enrollment information.
Where is the NCT03932903 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT03932903 clinical trial?
NCT03932903 is sponsored by Northwestern University. The principal investigator is Alexandra M Psihogios, Ph.D. at Northwestern University. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.